Keywords: Actelion, selexipag, Pulmonary arterial hypertension, PAH, REVEAL study, Patient care

Actelion reports strong Ph II data with selexipag; says REVEAL study may advance patient care in PAH

Article | 18 May 2010

Print This

Swiss biotechnology firm Actelion says that full data from the Phase II study of selexipag (proposed INN), the company's first-in-class, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in